KZR
Price:
$6.45
Market Cap:
$47.06M
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. ...[Read more]
Industry
Biotechnology
IPO Date
2018-06-21
Stock Exchange
NASDAQ
Ticker
KZR
According to Kezar Life Sciences, Inc.’s latest financial reports and current stock price. The company's current ROE is -59.73%. This represents a change of 301.82% compared to the average of -14.86% of the last 4 quarters.
The mean historical ROE of Kezar Life Sciences, Inc. over the last ten years is -13.77%. The current -59.73% ROE has changed 333.65% with respect to the historical average. Over the past ten years (40 quarters), KZR's ROE was at its highest in in the December 2017 quarter at 8.95%. The ROE was at its lowest in in the March 2017 quarter at -21.00%.
Average
-13.77%
Median
-25.63%
Minimum
-54.31%
Maximum
51.58%
Discovering the peaks and valleys of Kezar Life Sciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 124.40%
Maximum Annual ROE = 51.58%
Minimum Annual Increase = -164.22%
Minimum Annual ROE = -54.31%
Year | ROE | Change |
---|---|---|
2023 | -54.31% | 124.40% |
2022 | -24.20% | -10.57% |
2021 | -27.06% | -2.15% |
2020 | -27.66% | -31.54% |
2019 | -40.40% | 89.73% |
2018 | -21.29% | -164.22% |
2017 | 33.16% | -35.72% |
The current ROE of Kezar Life Sciences, Inc. (KZR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-35.19%
5-year avg
-34.73%
10-year avg
-13.77%
Kezar Life Sciences, Inc.’s ROE is greater than Century Therapeutics, Inc. (-66.58%), greater than Mineralys Therapeutics, Inc. (-55.92%), greater than Nkarta, Inc. (-27.13%), greater than NGM Biopharmaceuticals, Inc. (-55.66%), greater than Surrozen, Inc. (-222.75%), greater than Bolt Biotherapeutics, Inc. (-69.46%), greater than Larimar Therapeutics, Inc. (-35.87%), greater than Keros Therapeutics, Inc. (-41.74%), greater than Lyell Immunopharma, Inc. (-34.64%), greater than Cullinan Oncology, Inc. (-26.54%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Theseus Pharmaceuticals, Inc. (-12.35%), greater than Revolution Medicines, Inc. (-33.67%), less than Foghorn Therapeutics Inc. (167.93%), greater than Shattuck Labs, Inc. (-61.92%), greater than Kymera Therapeutics, Inc. (-24.96%), greater than Nurix Therapeutics, Inc. (-63.39%), greater than Design Therapeutics, Inc. (-18.01%), greater than Werewolf Therapeutics, Inc. (-58.83%), greater than Ikena Oncology, Inc. (-39.59%), greater than Stoke Therapeutics, Inc. (-54.45%),
Company | ROE | Market cap |
---|---|---|
-66.58% | $86.30M | |
-55.92% | $624.85M | |
-27.13% | $160.54M | |
-55.66% | $128.53M | |
-222.75% | $39.06M | |
-69.46% | $19.65M | |
-35.87% | $243.42M | |
-41.74% | $682.14M | |
-34.64% | $182.72M | |
-26.54% | $708.34M | |
-62.68% | $435.59M | |
-12.35% | $181.50M | |
-33.67% | $8.07B | |
167.93% | $274.07M | |
-61.92% | $52.51M | |
-24.96% | $2.65B | |
-63.39% | $1.38B | |
-18.01% | $355.01M | |
-58.83% | $68.63M | |
-39.59% | $76.73M | |
-54.45% | $598.53M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kezar Life Sciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kezar Life Sciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Kezar Life Sciences, Inc.'s ROE?
How is the ROE calculated for Kezar Life Sciences, Inc. (KZR)?
What is the highest ROE for Kezar Life Sciences, Inc. (KZR)?
What is the 3-year average ROE for Kezar Life Sciences, Inc. (KZR)?
What is the 5-year average ROE for Kezar Life Sciences, Inc. (KZR)?
How does the current ROE for Kezar Life Sciences, Inc. (KZR) compare to its historical average?